400 related articles for article (PubMed ID: 16912205)
1. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
2. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
3. BCG prophylaxis in bladder cancer produces activation of recruited neutrophils.
Vita F; Siracusano S; Abbate R; Ciciliato S; Borelli V; Soranzo MR; Zabucchi G
Can J Urol; 2011 Feb; 18(1):5517-23. PubMed ID: 21333042
[TBL] [Abstract][Full Text] [Related]
4. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.
Brincks EL; Risk MC; Griffith TS
Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637
[TBL] [Abstract][Full Text] [Related]
5. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy.
Reale M; Intorno R; Tenaglia R; Feliciani C; Barbacane RC; Santoni A; Conti P
Cancer Immunol Immunother; 2002 Apr; 51(2):91-8. PubMed ID: 11904733
[TBL] [Abstract][Full Text] [Related]
6. The role of granulocytes following intravesical BCG prophylaxis.
Siracusano S; Vita F; Abbate R; Ciciliato S; Borelli V; Bernabei M; Zabucchi G
Eur Urol; 2007 Jun; 51(6):1589-97; discussion 1597-9. PubMed ID: 17222501
[TBL] [Abstract][Full Text] [Related]
7. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
8. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
11. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
12. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
13. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
14. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
15. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
[TBL] [Abstract][Full Text] [Related]
16. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
Dovedi SJ; Kirby JA; Atkins H; Davies BR; Kelly JD
J Urol; 2005 Jul; 174(1):332-7; discussion 337. PubMed ID: 15947685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
